These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 21400720)

  • 1. [Metabolic syndrome in patients with chronic hepatitis C genotype 1].
    Baĭzhanova ZhZh; Ignatova TM; Nekrasova TP; Abdurakhmanov DT
    Vestn Ross Akad Med Nauk; 2011; (1):3-7. PubMed ID: 21400720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic steatosis in genotype 4 chronic hepatitis C patients: implication for therapy.
    Khattab MA; Abdel-fattah ME; Eslam M; Abdelaleem A; Abdelaleem RA; Shatat M; Ali A; Hamdy L; Tawfek H
    J Clin Gastroenterol; 2010; 44(10):707-12. PubMed ID: 20195166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon alpha-2a plus ribavirin.
    Reddy KR; Govindarajan S; Marcellin P; Bernstein D; Dienstag JL; Bodenheimer H; Rakela J; Messinger D; Schmidt G; Ackrill A; Hadziyannis SJ
    J Viral Hepat; 2008 Feb; 15(2):129-36. PubMed ID: 18184196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between insulin resistance and outcome of pegylated interferon and ribavirin therapy, hepatic steatosis, hepatic fibrosis in chronic hepatitis C-1b and high viral load.
    Kim SR; Saito J; Imoto S; Komaki T; Nagata Y; Nakajima T; Ando K; Fukuda K; Otono Y; Kim KI; Ohtani A; Sugimoto K; Hasegawa Y; Fujinami A; Ohta M; Hotta H; Maekawa Y; Hayashi Y; Kudo M
    Digestion; 2011; 84 Suppl 1():5-9. PubMed ID: 22156479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of insulin resistance and hepatic steatosis in the progression of fibrosis and response to treatment in hepatitis C.
    Sanyal AJ
    Liver Int; 2011 Jan; 31 Suppl 1():23-8. PubMed ID: 21205134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of fatty liver and related factors on the efficacy of combination antiviral therapy in patients with chronic hepatitis C.
    Jian Wu Y; Shu Chen L; Gui Qiang W
    Liver Int; 2006 Mar; 26(2):166-72. PubMed ID: 16448454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis.
    Soresi M; Tripi S; Franco V; Giannitrapani L; Alessandri A; Rappa F; Vuturo O; Montalto G
    Liver Int; 2006 Nov; 26(9):1119-25. PubMed ID: 17032413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients.
    Khattab M; Eslam M; Sharwae MA; Shatat M; Ali A; Hamdy L
    Am J Gastroenterol; 2010 Sep; 105(9):1970-7. PubMed ID: 20234345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin resistance and response to telaprevir plus peginterferon α and ribavirin in treatment-naive patients infected with HCV genotype 1.
    Serfaty L; Forns X; Goeser T; Ferenci P; Nevens F; Carosi G; Drenth JP; Lonjon-Domanec I; DeMasi R; Picchio G; Beumont M; Marcellin P
    Gut; 2012 Oct; 61(10):1473-80. PubMed ID: 22387529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1.
    Walsh MJ; Jonsson JR; Richardson MM; Lipka GM; Purdie DM; Clouston AD; Powell EE
    Gut; 2006 Apr; 55(4):529-35. PubMed ID: 16299039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppressor of cytokine signaling 3 (SOCS3) expression and hepatitis C virus-related chronic hepatitis: Insulin resistance and response to antiviral therapy.
    Persico M; Capasso M; Persico E; Svelto M; Russo R; Spano D; Crocè L; La Mura V; Moschella F; Masutti F; Torella R; Tiribelli C; Iolascon A
    Hepatology; 2007 Oct; 46(4):1009-15. PubMed ID: 17668875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection.
    Westin J; Lagging M; Dhillon AP; Norkrans G; Romero AI; Pawlotsky JM; Zeuzem S; Schalm SW; Verheij-Hart E; Negro F; Missale G; Neumann AU; Hellstrand K;
    J Viral Hepat; 2007 Jan; 14(1):29-35. PubMed ID: 17212641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical implications of hepatic steatosis in patients with chronic hepatitis C: a multicenter study of U.S. veterans.
    Hu KQ; Currie SL; Shen H; Cheung RC; Ho SB; Bini EJ; McCracken JD; Morgan T; Bräu N; Schmidt WN; Jeffers L; Wright TL;
    Dig Dis Sci; 2007 Feb; 52(2):570-8. PubMed ID: 17226072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advanced hepatic fibrosis and steatosis are associated with persistent alanine aminotransferase elevation in chronic hepatitis C patients negative for hepatitis C virus RNA during pegylated interferon plus ribavirin therapy.
    Liang CC; Liu CH; Chung CS; Lin CK; Su TH; Yang HC; Liu CJ; Chen PJ; Chen DS; Kao JH
    J Infect Dis; 2015 May; 211(9):1429-36. PubMed ID: 25387585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort study.
    Giordanino C; Bugianesi E; Smedile A; Ciancio A; Abate ML; Olivero A; Pellicano R; Cassader M; Gambino R; Bo S; Ciccone G; Rizzetto M; Saracco G
    Am J Gastroenterol; 2008 Oct; 103(10):2481-7. PubMed ID: 18702647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C-related Child's class A cirrhosis.
    Pearlman BL; Ehleben C; Perrys M
    Gastroenterology; 2015 Apr; 148(4):762-70.e2; quiz e11-2. PubMed ID: 25557952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Metabolic syndrome and insulin resistance in patients with chronic hepatitis C].
    Baĭzhanova ZhZh; Ignatova TM; Nekrasova TP
    Ter Arkh; 2010; 82(10):51-6. PubMed ID: 21341465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of metabolic syndrome, viral genotype and antiviral therapy on superimposed fatty liver disease in chronic hepatitis C.
    Liu CJ; Jeng YM; Chen PJ; Lai MY; Yang HC; Huang WL; Kao JH; Chen DS
    Antivir Ther; 2005; 10(3):405-15. PubMed ID: 15918331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adipokines and insulin resistance, predictors of response to therapy in Egyptian patients with chronic hepatitis C virus genotype 4.
    Saad Y; Ahmed A; Saleh DA; Doss W
    Eur J Gastroenterol Hepatol; 2013 Aug; 25(8):920-5. PubMed ID: 23442415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.